This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06731/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06731/identifier/wikipedia/
n5http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB06731/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06731/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB06731/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06731/identifier/iuphar/
n8http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06731/identifier/guide-to-pharmacology/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB06731
rdf:type
n3:Drug
n3:description
Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
n3:group
investigational
n3:halfLife
4-16 days
owl:sameAs
n5:DB06731 n16:DB06731
dcterms:title
Seproxetine
adms:identifier
n7:Seproxetine n10:DB06731 n11:208 n12:4382 n13:99443277 n14:208 n15:4541
n3:mechanismOfAction
Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
n3:synonym
(S)-norfluoxetine
n3:salt
n3:IUPAC-Name
n8:271B522E-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B5234-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B5233-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B5230-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B5231-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B5232-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B522C-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B522D-363D-11E5-9242-09173F13E4C5 n8:271B522A-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B522B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n8:271B523A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B523B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B5235-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B5236-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B5238-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B5237-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B5239-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
126924-38-7
n3:Bioavailability
n8:271B523F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B5241-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B5242-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B523E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B523D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B5240-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B522F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B523C-363D-11E5-9242-09173F13E4C5